Q-omics provides the consensus-scored STK16P1 profile across patient tissues and cancer cell-line models. STK16P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STK16P1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, STK16P1 RNA expression shows 16,133 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where STK16P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STK16P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STK16P1 survival associations across molecular data types. STK16P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STK16P1 RNA expression–survival associations across cancer types. High STK16P1 expression shows unfavorable associations in KIRC, KICH, LIHC, BLCA, ACC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for STK16P1 RNA expression.
This table summarizes STK16P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for STK16P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STK16P1 shows higher tumor expression in BLCA, LUSC, COAD, KIRC, BRCA and LIHC. The BLCA box plot shows higher STK16P1 RNA expression in tumor versus normal tissue (log2 FC = +0.284, t-test p < 0.001).
This table shows molecular features associated with STK16P1 in patient tissues and cancer cell lines. In patient samples, STK16P1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
